Synergy Pharmaceuticals (SGYP) Posts Earnings Results

Share on StockTwits

Synergy Pharmaceuticals (NASDAQ:SGYP) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01), MarketWatch Earnings reports. The business had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million.

Shares of NASDAQ:SGYP traded down $0.09 during midday trading on Friday, hitting $0.36. 9,599,730 shares of the company’s stock traded hands, compared to its average volume of 7,622,059. The firm has a market capitalization of $114.13 million, a price-to-earnings ratio of -0.35 and a beta of 2.38. Synergy Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.

Several research firms recently weighed in on SGYP. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Synergy Pharmaceuticals in a report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, August 14th. BidaskClub lowered shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 12th. Canaccord Genuity lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Finally, BTIG Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. Synergy Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.17.

ILLEGAL ACTIVITY WARNING: This story was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://weekherald.com/2018/11/10/synergy-pharmaceuticals-sgyp-posts-earnings-results.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Featured Story: Fiduciary

Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply